A biotechnology company specializing in next-generation treatments has struck a significant partnership deal with one of the world’s largest pharmaceutical manufacturers to advance a promising autoimmune therapy.
Kali Therapeutics announced Monday that it has formed a licensing partnership with Sanofi, the French pharmaceutical giant, to further develop the company’s experimental autoimmune disease treatment called KT501.
The financial terms of the agreement are substantial. Kali Therapeutics will collect $180 million in immediate and short-term payments, with the potential to earn an additional $1.05 billion through various development and sales milestones. Should the treatment receive regulatory approval, the company will earn royalty payments ranging from high single-digit to double-digit percentages on product sales.
Through this partnership, Sanofi gains worldwide rights to KT501, which represents a tri-specific antibody created using Kali Therapeutics’ proprietary research platform. The experimental drug is currently undergoing early-phase clinical testing in rheumatoid arthritis patients to evaluate safety and patient tolerance levels.
According to Kali Therapeutics, the treatment is engineered to target and regulate immune cells responsible for triggering autoimmune conditions, including diseases like lupus and rheumatoid arthritis. Laboratory studies conducted on non-human primates demonstrated that KT501 significantly decreased B cell populations—a type of white blood cell—while minimizing the dangerous immune responses sometimes associated with comparable therapies.
Sanofi brings existing expertise in autoimmune treatments to the partnership, currently selling Kevzara, an approved rheumatoid arthritis medication developed in collaboration with Regeneron Pharmaceuticals. The company is simultaneously working on additional anti-inflammatory drug candidates in its pipeline.
